Hydromorphone controlled-release - Avadel Pharmaceuticals
Alternative Names: FT 227; Hydromorphone extended-release - Avadel; Trigger Lock™ hydromorphoneLatest Information Update: 17 Feb 2026
At a glance
- Originator Flamel Technologies
- Developer Avadel Pharmaceuticals
- Class Morphine derivatives; Opioid analgesics; Small molecules
- Mechanism of Action Opioid receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Pain
Highest Development Phases
- No development reported Pain
Most Recent Events
- 12 Feb 2026 Avadel Pharmaceuticals has been acquired by Alkermes plc
- 28 Jul 2018 No recent reports of development identified for phase-I development in Pain(In volunteers) in France (PO, Controlled release)
- 28 Mar 2017 Avadel's Hydromorphone controlled-release is available for licensing as of 28 Mar 2017. http://www.avadel.com/